University of Manchester scientists have mapped the mutations in the tiny protein chains that cause a subtype of muscular ...

Managing osteoporosis and bone health in Duchenne muscular dystrophy occurs in a high-risk environment for fractures due to ...

DYNE-251 received FDA breakthrough therapy designation, showcasing its potential for patients with Duchenne muscular ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

A cell therapy preserves muscle structure and function in laboratory mice with a type of disease similar to Duchenne muscular ...

For adults with Duchenne muscular dystrophy, swallowing-related impairments are associated with age, inspiratory muscle strength, and autonomic dysfunction, say the results of a new study. CMR ...

Duchenne Muscular Dystrophy affects 12,000 to 15,000 children and young adults in the United States and about 300,000 worldwide. It's caused by a mutation in the dystrophin gene, which makes a ...

Duchenne muscular dystrophy has a prevalence of 1 in 35,000 males. [12] The symptoms of Duchenne muscular dystrophy initially include delayed motor milestones and weakness of the proximal muscles ...

Delandistrogene moxeparvovec, a gene therapy for Duchenne muscular dystrophy (DMD), showed high dystrophin expression and a favorable safety profile in young patients. Delandistrogene moxeparvovec ...

The Health Resources and Services Administration is requesting public comments on its recommendation to add metachromatic ...

COALITION Duchenne's 13th annual Expedition Mt Kinabalu will start tomorrow from Shangri-La's Tanjung Aru Resort and Spa, ...

Global Duchenne Muscular Dystrophy Drugs Market Report 2023: Sector is Expected to Reach $4 Billion by 2028 at a CAGR of 11.88% - ResearchAndMarkets.com May 18, 2023 07:21 AM Eastern Daylight Time ...